(1S,2R)-Bortezomib-d5
CAS: 1132709-16-0
Rif. 3D-HVB70916
5mg | Fuori produzione | ||
10mg | Fuori produzione | ||
25mg | Fuori produzione | ||
50mg | Fuori produzione | ||
100mg | Fuori produzione |
Informazioni sul prodotto
(1S,2R)-Bortezomib-d5 is a modified form of bortezomib that has been radiolabeled with d5. It is an apoptotic agent that inhibits the proteasome pathway and induces apoptosis. Bortezomib-d5 has shown promising results in clinical trials for the treatment of lymphocytic leukemia, chronic lymphocytic leukemia, and multiple myeloma. The drug causes thrombocytopenia as a toxic effect.